Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Novartis ag crawled date : 2022 - 05 - 05 save search
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
Published: 2022-05-05 (Crawled : 21:00) - investors.biomarin.com
GLAXF | $20.2 0.65% -14.18% 40
|
Health Technology
|
| O: -1.11%
H: 2.28%
C: -0.39%
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -10.81%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
GSK | $39.27 -0.83% 0.26% 1.9M
|
Health Technology
|
| O: -1.32%
H: 0.75%
C: 0.2%
BMRN S | $90.07 -0.44% -0.43% 780K
|
Health Technology
|
| O: -1.18%
H: 1.07%
C: -2.15%
growth
Global Asthma and COPD Drugs Market Report to 2030 - Opportunity Analysis and Industry Forecasts
Published: 2022-05-05 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 40
|
Health Technology
|
| O: 0.18%
H: 0.46%
C: 0.46%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.98%
H: 0.0%
C: -2.72%
AZNCF | $138.24 -1.36% -4.19% 800
|
Health Technology
|
| O: -0.86%
H: 1.57%
C: -0.42%
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
GSK | $39.27 -0.83% 0.26% 1.9M
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: 0.0%
ABT | News | $105.27 -0.6% -0.38% 5.9M
|
Health Technology
|
| O: -0.73%
H: 0.12%
C: -1.61%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 3.6M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
report market drug
BeiGene Reports First Quarter 2022 Financial Results
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
BGNE | $131.96 0.08% 0.06% 110K
|
Health Technology
|
| O: 0.98%
H: 7.7%
C: -2.09%
results
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | $92.57 -0.55% 0.27% 840K
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 3.73%
H: 0.09%
C: -3.98%
jakavi treatment disease approval
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
TPET | $0.3279 -3.56% 28.48% 33M
|
n/a
GDHG | $0.263 21.76% 25.34% 1.3M
|
HOLO | $2.95 31.7% 22.49% 37M
|
UMAC | $1.55 0.65% 16.13% 3K
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
VLD 4 | $0.2638 -3.65% 13.27% 2.6M
|
Manufacturing
ALLR | $1.54 2.67% 11.76% 740K
|
n/a
MGLD 4 | $1.13 5.61% 10.62% 200
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.